Tel.: +49 6221 868023
Fax: +49 6221 8680255
info@loxo.de

Pefachrome® FXIIa/TH 5253, Chromogenic Substrate for Thrombin

Application:
Highly sensitive chromogenic peptide substrate for factor XIIa. Determination of factor XIIa activity for research, in-process and quality control. 

Formula: H-D-CHA-Gly-Arg-pNA · 2AcOH

MW: 624.7 

Principle: H-D-CHA-Gly-Arg-pNA + FXIIa ==> H-D-CHA-Gly-Arg-OH + pNA + FXIIa 

KM: 0.8 mM

vmax:  3.14 µmol/min 

Solubility: Up to 4 mM in H2

Storage:
May be used by the expiry date given on the label when stored unopened, protected from moisture, in the dark, 2-8°C. Avoid contamination of the reagents by micro-organisms. Shipment of product does not require cooling during the time of transportation. 

Material required but not provided: 
Buffer, NaCl, reference material, dist. H2O, Pefabloc® PK, Kalliplastin®

Buffer:
50 mM Tris-imidazole buffer pH 7.9, 150 mM NaCl

Assay 1:
Suggested protocol for the determination of factor XIIa activity:
0.700 ml buffer 
0.100 ml factor XIIa (0.2 units/ml)
0.200 ml Pefachrome®6017 4 mM
==> Determination of ∆OD/min at 405 nm

Assay 2:
Suggested protocol for the determination of factor XIIa activity (FXII activated by Kalliplastin®) using Pefachrome®6017 and a selective synthetic inhibitor of plasma kallikrein (Pefabloc® PK):
0.100 ml citrated plasma (diluted 1:5 with NaCl)
0.200 ml Kalliplastin® (20 µg/ml, Pentapharm Ltd.)
> incubate for 1 min at 37 °C
0.500 ml buffer
0.100 ml Pefabloc® PK 0.2 mM
0.100 ml Pefachrome®6017 2 mM
==> Determination of ∆OD/min at 405 nm

Category: Research use only

Type: Substrate

Product Availability: Germany, Israel and Egypt

Manufacturer: DSM Nutritional Products Ltd. Branch Pentapharm, Switzerland


For more information please click .pdf icon below.


Pefachrome FXIIa/TH 5253

Chromogenic Substrate for Thrombin
Article no.: 808111/25

Unit: 25 mg

Code: 081-11

Manufacturer: Pentapharm AG

References

  1. Stürzebecher J, Svendsen L, Eichenberger R, Markwardt F.
    A new assay for the determination of factor XII in plasma using a chromogenic substrate and a selective inhibitor of plasma kallikrein.
    Thromb Res 1989; 55: 709-15. 

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzerklärung X